There are currently 72 clinical trials in Mesa, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Banner Children's at Desert, GSK Investigational Site, Pfizer Investigational Site and Banner Desert Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/17/2025
Locations: Banner Children's at Desert, Mesa, Arizona
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa, Mesa, Arizona
Conditions: Psoriatic Arthritis, Overweight or Obesity
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
04/17/2025
Locations: Care Access - 801 South Power Road, Mesa, Mesa, Arizona
Conditions: Alzheimer Disease
Register for Updates
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257
Recruiting
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplat... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
04/16/2025
Locations: Banner Children's at Desert, Mesa, Arizona
Conditions: Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Register for Updates
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
NCT06933836
Recruiting
DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/16/2025
Locations: Barnet Dulaney Perkins Eye Centers, Mesa, Arizona
Conditions: Open Angle Glaucoma (OAG)
Register for Updates
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
NCT06312020
Recruiting
The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/16/2025
Locations: Arizona Arthritis & Rheumatology Research-S Vineyard Ave, Mesa, Arizona
Conditions: Sjogren's Syndrome
Register for Updates
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Banner Heart Hospital, Mesa, Arizona
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Register for Updates
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
04/16/2025
Locations: AKDHC Medical Research Service LLC - Banner Desert Office, Mesa, Arizona
Conditions: Proteinuric Kidney Disease
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
04/16/2025
Locations: Care Access - 801 South Power Road, Mesa, Mesa, Arizona
Conditions: Alzheimer's Disease
Register for Updates
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496
Recruiting
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ, Mesa, Arizona
Conditions: Psoriatic Arthritis
Register for Updates
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852
Recruiting
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/15/2025
Locations: Ironwood Cancer & Research Centers, Mesa, Arizona +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
NCT05039840
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Arizona Arthritis & Rheumatology Associates - South Vineyard Avenue- Site Number : 8400022, Mesa, Arizona
Conditions: Systemic Lupus Erythematosus
Register for Updates